CORT Corcept Therapeutics margins

Relative Growth: Rel. Growth: 78

Relative Strength: Rel. Strength: 81

Relative Valuation: Rel. Valuation: 8

Relative Profitability: Rel. Profitability: 45

Gross margin

98.3%

Operating margin

0.8%

EBITDA margin

0.9%

Net margin

6.5%

Currently, Corcept Therapeutics has a gross margin of 98.3%, an operating margin of 0.8%, an EBITDA margin of 0.9%, and a net margin of 6.5%. Each available margin declined from the same period last year. Operating margin recorded the strongest contraction, decreasing by 13.4 percentage points.

CORT margin history

Gross, operating, EBITDA and net margin trends

Corcept Therapeutics's margins averaged 98.4% gross, 14.17% operating, 14.26% EBITDA, and 16.95% net during the last 3 years. Currently, all four current margins are below their three-year averages.

CORT margin expansion

Year-over-year margin changes in percentage points

Operating and EBITDA margins led the decline, falling by 13.4 percentage points, while the other available margins also decreased.

Gross margin expansion

-0.1pp

Operating margin expansion

-13.4pp

EBITDA margin expansion

-13.4pp

Net margin expansion

-11.9pp

CORT Gross margin

Corcept Therapeutics's gross margin averaged 98.4% across the past 3 years. Against its three-year average, Corcept Therapeutics's gross margin is currently 98.3%, 0.1 percentage points below its three-year average. Over the last 3 years, Corcept Therapeutics's gross margin peaked at 98.7% in Dec 2023 and reached a low of 98.2% in Sep 2025.

CORT Operating margin

Over the last 3 years, the average operating margin for Corcept Therapeutics was 14.17%. The latest operating margin for Corcept Therapeutics is 0.8%, 13.4 percentage points below its three-year average. Corcept Therapeutics's operating margin ranged from a low of -1.1% in Mar 2026 to a high of 23.3% in Mar 2024.

CORT EBITDA margin

Over the last 3 years, the average EBITDA margin for Corcept Therapeutics was 14.26%. The latest EBITDA margin for Corcept Therapeutics is 0.9%, 13.4 percentage points below its three-year average. Corcept Therapeutics's EBITDA margin ranged from a low of -0.9% in Mar 2026 to a high of 23.5% in Mar 2024.

CORT Net margin

Over the last 3 years, the average net margin for Corcept Therapeutics was 16.95%. The latest net margin for Corcept Therapeutics is 6.5%, 10.5 percentage points below its three-year average. Corcept Therapeutics's net margin ranged from a low of 6.1% in Mar 2026 to a high of 22.4% in Mar 2024.

CORT margin group comparison

Margins compared with peer-group, industry and sector averages

Corcept Therapeutics's gross margin of 98.3% is above the Healthcare sector, the industry and its peers average. Looking at its Healthcare sector average of 68.3%, Corcept Therapeutics's gross margin is 44% higher.

CORT margin peer comparison

Compare margins with selected peers

Frequently asked questions

What is Corcept Therapeutics's gross margin?

For the period ending Jun 30, 2026, CORT recorded a gross margin of 98.3%.

What is Corcept Therapeutics's operating margin?

The current operating margin for CORT is 0.8% as of Jun 30, 2026.

What is Corcept Therapeutics's EBITDA margin?

The current EBITDA margin for CORT is 0.9% as of Jun 30, 2026.

What is Corcept Therapeutics's net margin?

As of Jun 30, 2026, CORT has a net margin of 6.5%.

What are the average margins of CORT?

Corcept Therapeutics's gross, operating, EBITDA, and net margins averaged 98.4% gross, 14.2% operating, 14.3% EBITDA, and 17.0% net over the last 3 years.

What are the highest historical margins of CORT?

Corcept Therapeutics's highest recorded margins during the past 5 years were 98.7% gross in Dec 2023, 34.6% operating in Mar 2022, 35.5% EBITDA in Mar 2022, and 30.7% net in Dec 2021.

What are the lowest historical margins of CORT?

Over the last 5 years, Corcept Therapeutics's lowest margins were 98.2% gross in Sep 2025, -1.1% operating in Mar 2026, -0.9% EBITDA in Mar 2026, and 6.1% net in Mar 2026.